Pharmafile Logo

Free Thinking: Biosimilars: Friend or foe to healthcare?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.

Biologics, whose active substance is derived from a living organism, have enabled healthcare to make significant therapeutic advances across a whole raft of therapy areas since their introduction in the 1970s. However, these medicines come at a price, reflecting the complexities involved in developing and manufacturing products derived from living cells. Annual treatment costs in the US can range from US$25,000 to US$200,000.

Biosimilars medicines, the follow-on “generics” to biologics which have come off-patent, present a significant opportunity to introduce cutting-edge therapies to the treatment landscape for many diseases, while also addressing the cost-effectiveness demands now being made on global healthcare systems. 

Download and read the complimentary whitepaper at http://bit.ly/1Gmknh7  

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges.

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Research Partnership launches new patient Living With Non-alcoholic Steatohepatitis (NASH) report

Living with Non-alcoholic Steatohepatitis (NASH) is a study conducted amongst 100 adults with NASH in the US. The study employs a mixed quantitative/qualitative methodology and will be available to purchase...

EULAR Annual European Congress of Rheumatology 2017

Join us at EULAR Congress 2017 in Madrid, 14-17 June

20 questions: Round 2

As it's our 20th year anniversary, we invited our employees to play our version of 20 questions - this month "What do you love about your job?"Watch the video: http://bit.ly/2qA1oP9

Taking an integrated approach to research

Director Melinda Shorr and Associate Director Steven Helm discuss the benefits of integrated research techniques.Watch the video: http://bit.ly/2qF0qO2

Online Community Research

What to consider when running an online research community?

Research Partnership appoints Helen Parfitt as Director, Head of Therapy Watch

Helen Parfitt has joined Research Partnership as Head of Therapy Watch at the company’s global head office in London. Therapy Watch is a ‘real-time’ syndicated global market tracking tool that...

Research Partnership is expanding its US capabilities with new offices opening in San Francisco and New York

Research Partnership is today expanding its US operations across both the West and East Coast. Director Tom Winter has relocated from London and is today opening a new office in...

A safe place to talk about Crohn’s

Published in eyeforpharma April 2017 by Mariel Metcalfe

Patient Assistance Programme Evaluation for Cardiovascular Conditions

Our client had launched a self-injection treatment for cardiovascular conditions and were creating an accompanying Patient Assistance Programme (PAP) to educate patients in the use and uptake of this product.Read the case...

What next for the treatment of Psoriasis in Europe?

Research Director Laurent Chanroux investigates the changing market dynamics in Psoriasis in Europe.